Botulinum Toxin Drug Landscape
As of 2026-11-14, products from AbbVie, Ipsen, Merz, Korea’s Hugel and Daewoong had US glabellar-line approvals; Taiwan’s OBI-858 remained in Phase 3.
OBIGEN reported on 2026-09-07 that over half of participants received only 1 or 2 treatments during its one-year repeat-dose Phase 2; this does not replace Phase 3 primary endpoints.
OBIGEN still targeted Phase 3 completion in 2026 in its 2026-09-07 announcement, followed by a registration application; pivotal endpoint results will determine its progress toward approved products.
Type A botulinum toxins for glabellar lines. Potency units are product-specific and are not interchangeable; duration is not ranked across separate trials.
Competitive landscape
| Asset | Company | Mechanism / route | Stage | Indication | Trial identifier | Deal | Latest development | Source |
|---|---|---|---|---|---|---|---|---|
| Botox Cosmetic / onabotulinumtoxinA | AbbVieUS | Botulinum neurotoxin type AIntramuscular | US approved | Glabellar lines and label-specific indications | — | — | Established approved product; units are not interchangeable | dailymed.nlm.nih.gov |
| Dysport / abobotulinumtoxinA | IpsenFrance | Botulinum neurotoxin type AIntramuscular | US approved | Glabellar lines and label-specific indications | — | — | Ipsen product; aesthetic commercialization rights are distinct | dailymed.nlm.nih.gov |
| Xeomin / incobotulinumtoxinA | MerzGermany | Botulinum neurotoxin type AIntramuscular | US approved | Upper facial lines, per label | — | — | Glabellar-line evidence on label; molecular size does not prove duration | dailymed.nlm.nih.gov |
| Letybo / letibotulinumtoxinA | HugelSouth Korea | Botulinum neurotoxin type AIntramuscular | US approved | Adult moderate-to-severe glabellar lines | — | — | FDA approval 2024-02-29; 1,271 participants across three trials | fda.gov |
| Jeuveau / prabotulinumtoxinA | Daewoong (manufacturer) / Evolus (US commercialization)South Korea / US | Botulinum neurotoxin type AIntramuscular | US approved | Adult moderate-to-severe glabellar lines | — | — | FDA review identifies Daewoong as manufacturer | accessdata.fda.gov |
| OBI-858 | OBIGEN PharmaTaiwan | 760 kDa type A toxin complexIntramuscular | Taiwan Phase 3 | Moderate-to-severe glabellar lines | OBI-858-004 OBI-858-005 | — | Two Phase 3 trials: about 600 participants, 16 centers; primary endpoint: GLS improvement ≥2 grades at Week 4; repeat-dose Phase 2 completed | obigenpharma.comobigenpharma.com |
Taiwan and Asia
Taiwan’s OBIGEN announced enrollment of approximately 600 participants across 16 centers in its two pivotal trials on 2026-03-16; a US Phase 2 IND is distinct from marketing approval. Korea’s Hugel Letybo and Daewoong-manufactured, Evolus-marketed Jeuveau have US approvals.